Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107630 | 0.86 | BCL2 (0.44) | KMT2ATGM2 | |
| SCHEMBL9107293 | 0.82 | CCKBR (0.39) | MEN1KMT2ATGM2ELANE | |
| SCHEMBL9107681 | 0.81 | MAPT (0.49) | SMN1; SMN2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9104273 | 0.78 | NPSR1 (0.43) | SMN1; SMN2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9105927 | 0.77 | GCK (0.45) | MEN1KMT2AALDH1A1 | |
| SCHEMBL9108726 | 0.77 | NPSR1 (0.42) | SMN1; SMN2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL281692 | 0.77 | KMT2A (0.40) | MEN1KMT2AMAPTALDH1A1TGM2 | |
| SCHEMBL9908080 | 0.77 | GCK (0.41) | SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL9101953 | 0.76 | GCK (0.66) | MEN1KMT2AALDH1A1 | |
| SCHEMBL9106900 | 0.76 | KDM4E (0.44) | MEN1KMT2AMAPTTGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | KESTER ROBERT FRANCIS (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142705-A1 | ISATIN AND OXINDOLE COMPOUNDS | GPR119, INSR, OAT | SMN1; SMN2 1483/4885MEN1 2086/4885CYP1A2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.